Formulation: A solid
Formal Name: (2S,18E,28E)-25S-(acetyloxy)-5,6,21S,23R-tetrahydroxy-27S-methoxy-2,4,11,16Z,20S,22R,24R,26R-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-d6-1,15(2H)-dione
Purity: ≥99% deuterated forms (d1-d6)
Formula Markup: C43H45D6N3O11
Formula Weight: 791,9
Shelf life (days): 1460
CAS Number: 1262992-43-7
Notes: Rifaximin-d6 is intended for use as an internal standard for the quantification of rifaximin (Item No. 16131) by GC- or LC-MS. Rifaximin is an antibiotic derived from rifamycin SV (Item No. 21441) that inhibits the growth of a variety of Gram-positive and Gram-negative bacteria in vitro, including Staphylococcus, Streptococcus, Enterococcus, H. influenzae, and N. gonorrhoeae (MIC50s = ≤0.015, 50 = ~20 μM) that reduces colonic damage, rectal bleeding, and diarrhea in PXR-humanized, but not wild-type or Pxr-null, mice with inflammatory bowel disease (IBD) induced by dextran sulfate sodium (DSS; Item No. 23250).{42471,42472} Rifaximin exhibits minimal intestinal absorption after oral administration and is, therefore, effective in eliminating bacteria in the gastrointestinal system.{26322,26320} Formulations containing rifaximin have been used in the treatment of traveler's diarrhea caused by noninvasive E. coli, irritable bowel syndrome with diarrhea (IBS-D), and to reduce the risk of recurrence of overt hepatic encephalopathy.
English
Deutsch
